LNTH INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

13.10.25 15:00 Uhr

Werte in diesem Artikel
Aktien

45,96 EUR -0,18 EUR -0,39%

SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Lantheus class action lawsuit – captioned Margolis v. Lantheus Holdings, Inc., No. 25-cv-07491 (S.D.N.Y.) – seeks to represent purchasers or acquirers of Lantheus Holdings, Inc. (NASDAQ: LNTH) securities and charges Lantheus as well as certain of Lantheus's executives with violations of the Securities Exchange Act of 1934.

Robbins Geller Rudman & Dowd LLP (PRNewsfoto/Robbins Geller Rudman & Dowd LLP)

If you suffered substantial losses and wish to serve as lead plaintiff of the Lantheus class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-lantheus-holdings-inc-class-action-lawsuit-lnth.html 

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.  Lead plaintiff motions for the Lantheus class action lawsuit must be filed with the court no later than Monday, November 10, 2025.

CASE ALLEGATIONS: Lantheus develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.  According to the complaint, Lantheus's key Radiopharmaceutical Oncology product is Pylarify, a PET imaging agent used to assist in both diagnosing and subsequently treating prostate cancer.

The Lantheus class action lawsuit alleges that defendants created the false impression that they possessed reliable information pertaining to Lantheus's projected revenue outlook and anticipated growth while also minimizing risk from competition and pricing dynamics, seasonality, and macroeconomic fluctuations.  In truth, according to the complaint, Lantheus's optimistic reports of Pylarify's sales growth potential and pricing normalization fell short of reality and Lantheus, despite defendants' claims, did not have an accurate understanding of the pricing and competitive dynamics of Pylarify's market.

The Lantheus class action lawsuit further alleges that on May 7, 2025, Lantheus reported its first quarter 2025 results, disclosing that Pylarify sales had decreased year-over-year due to an alleged "temporal competitive disruption."  The complaint alleges that defendants further reduced their previous full-year projections due to Pylarify's shortfall, reducing the "year-over-year range to flat-to-low single-digit percent growth for the full year versus our prior view of low-single-digit to mid-single-digit growth."  On this news, the price of Lantheus stock fell more than 23%, according to the complaint.

Then, on August 6, 2025, the Lantheus class action lawsuit further alleges that Lantheus again announced disappointing results and significantly reduced growth expectations for Pylarify, which had fallen 8.3% year-over-year, and slashed fiscal year 2025 growth projections further.  On this news, the price of Lantheus stock fell nearly 29%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Lantheus securities during the Class Period to seek appointment as lead plaintiff in the Lantheus class action lawsuit.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the Lantheus class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the Lantheus class action lawsuit.  An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Lantheus class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation.  Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors.  In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS.  With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.  Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 

Services may be performed by attorneys in any of our offices. 

Contact:
            Robbins Geller Rudman & Dowd LLP
            J.C. Sanchez, Jennifer N. Caringal
            655 W. Broadway, Suite 1900, San Diego, CA 92101
            800-449-4900
            info@rgrdlaw.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lnth-investor-notice-robbins-geller-rudman--dowd-llp-announces-that-lantheus-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-securities-class-action-lawsuit-302581455.html

SOURCE Robbins Geller Rudman & Dowd LLP

In eigener Sache

Übrigens: Lantheus und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Lantheus

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Lantheus

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Lantheus Holdings Inc

Wer­bung

Analysen zu Lantheus Holdings Inc

DatumRatingAnalyst
08.11.2016Lantheus OutperformRBC Capital Markets
24.02.2016Lantheus OutperformRBC Capital Markets
20.07.2015Lantheus OutperformRobert W. Baird & Co. Incorporated
20.07.2015Lantheus OutperformRBC Capital Markets
DatumRatingAnalyst
08.11.2016Lantheus OutperformRBC Capital Markets
24.02.2016Lantheus OutperformRBC Capital Markets
20.07.2015Lantheus OutperformRobert W. Baird & Co. Incorporated
20.07.2015Lantheus OutperformRBC Capital Markets
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Lantheus Holdings Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen